Search research articles
Contact Us
Filters
Showing results (1-10 of 195) with videos related to
Page
of 20
Sort By:
The Lancet. Gastroenterology & Hepatology
|
June 20, 2024
Broadening clinical indications of tenofovir alafenamide in chronic hepatitis B
Lung-Yi Mak
Alimentary Pharmacology & Therapeutics
|
March 15, 2019
Editorial: can hepatitis B core-related antigen be the new biomarker for hepatocellular carcinoma in nucleoside analogue-treated chronic hepatitis B?
Lung-Yi Mak
The Lancet. Gastroenterology & Hepatology
|
February 24, 2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide: perhaps not as simple as we thought
Lung-Yi Mak
Alimentary Pharmacology & Therapeutics
|
October 27, 2023
Editorial: HBsAg seroclearance after pegylated interferon treatment-The beginning of the end
Lung-Yi Mak
Clinical and Molecular Hepatology
|
February 1, 2024
Steatotic liver disease: Know your enemies
Lung-Yi Mak
Journal of Liver Cancer
|
August 5, 2024
Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma
Lung-Yi Mak
Hepatology International
|
January 28, 2022
Non-alcoholic fatty liver disease in cerebrovascular disease: a bystander or a real risk factor?
Lung-Yi Mak, James Fung
Hepatology International
|
June 18, 2021
The clinical and economic burden of non-alcoholic steatohepatitis in the Middle East: behind the scene
Lung-Yi Mak, James Fung
Alimentary Pharmacology & Therapeutics
|
August 10, 2023
Editorial: Mitigating the risk of severe hepatitis flare following nucleoside analogue discontinuation-Insights from a real-world study
Lung-Yi Mak, James Fung
Hepatology International
|
April 19, 2020
Proton pump inhibitors in chronic liver disease: accomplice or bystander?
Lung-Yi Mak, James Fung
Page
of 20
Search research articles
Search
Showing results (1-10 of 195) with videos related to
Sort By:
Page
of 20
The Lancet. Gastroenterology & Hepatology
|
June 20, 2024
Broadening clinical indications of tenofovir alafenamide in chronic hepatitis B
Lung-Yi Mak
Alimentary Pharmacology & Therapeutics
|
March 15, 2019
Editorial: can hepatitis B core-related antigen be the new biomarker for hepatocellular carcinoma in nucleoside analogue-treated chronic hepatitis B?
Lung-Yi Mak
The Lancet. Gastroenterology & Hepatology
|
February 24, 2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide: perhaps not as simple as we thought
Lung-Yi Mak
Alimentary Pharmacology & Therapeutics
|
October 27, 2023
Editorial: HBsAg seroclearance after pegylated interferon treatment-The beginning of the end
Lung-Yi Mak
Clinical and Molecular Hepatology
|
February 1, 2024
Steatotic liver disease: Know your enemies
Lung-Yi Mak
Journal of Liver Cancer
|
August 5, 2024
Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma
Lung-Yi Mak
Hepatology International
|
January 28, 2022
Non-alcoholic fatty liver disease in cerebrovascular disease: a bystander or a real risk factor?
Lung-Yi Mak, James Fung
Hepatology International
|
June 18, 2021
The clinical and economic burden of non-alcoholic steatohepatitis in the Middle East: behind the scene
Lung-Yi Mak, James Fung
Alimentary Pharmacology & Therapeutics
|
August 10, 2023
Editorial: Mitigating the risk of severe hepatitis flare following nucleoside analogue discontinuation-Insights from a real-world study
Lung-Yi Mak, James Fung
Hepatology International
|
April 19, 2020
Proton pump inhibitors in chronic liver disease: accomplice or bystander?
Lung-Yi Mak, James Fung
Page
of 20